Document Detail


Phase II study of high-dose cyclophosphamide in relapsing and/or resistant hepatoblastoma in children: a study from the SIOPEL group.
MedLine Citation:
PMID:  15454253     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The study sought to evaluate the response to cyclophosphamide (CPM) in hepatoblastoma (HB). Patients with a refractory or relapsing HB after first-line therapy as per SIOPEL 2 and 3 protocols were eligible. All patients were to receive two courses of CPM 2 g/m(2) on days 1 and 2 at 3-week intervals. Eighteen patients were included; 17 were evaluable for response. Prior treatment was cisplatinum alone (1 patient) or cisplatinum-carboplatin-doxorubicin (17 patients). The disease status at the beginning of CPM was: progressive during first-line treatment (10 patients), persistent unresectable disease at the end of the protocol (2 patients), relapse (6 patients). Tumour response was partial response (1 patient), stable disease (1 patient), progressive disease (15 patients) and not evaluable in one. All patients died, 17 of progressive disease and one of surgery complications. The low response rate (1/17) led the SIOPEL group to conclude that single-agent CPM is not effective for the treatment of relapsing or refractory HB.
Authors:
Walter Daniel Cacciavillano; Laurence Brugières; Margaret Childs; Elisabeth Shafford; Penelope Brock; Jon Pritchard; Rudolf Mailbach; Marcello Scopinaro; Giorgio Perilongo
Related Documents :
11205213 - The use erythrocyte glutathione as a predictive marker for malignant melanoma.
790693 - Prolongation effect of blood transfusions on kidney graft survival.
2742713 - Nuclear morphometric measurements in rectal adenocarcinoma cells of patients of differe...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of cancer (Oxford, England : 1990)     Volume:  40     ISSN:  0959-8049     ISO Abbreviation:  Eur. J. Cancer     Publication Date:  2004 Oct 
Date Detail:
Created Date:  2004-09-29     Completed Date:  2004-11-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9005373     Medline TA:  Eur J Cancer     Country:  England    
Other Details:
Languages:  eng     Pagination:  2274-9     Citation Subset:  IM    
Affiliation:
Department of Paediatric Oncology, Institut Gustave Roussy, Villejuif, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Antineoplastic Agents, Alkylating / administration & dosage*,  adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carboplatin / administration & dosage
Child
Child, Preschool
Cisplatin / administration & dosage
Cyclophosphamide / administration & dosage*,  adverse effects
Doxorubicin / administration & dosage
Female
Hepatoblastoma / drug therapy*
Humans
Liver Neoplasms / drug therapy*
Male
Middle Aged
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Alkylating; 15663-27-1/Cisplatin; 23214-92-8/Doxorubicin; 41575-94-4/Carboplatin; 50-18-0/Cyclophosphamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Protein kinase C alpha expression in normal breast, ductal carcinoma in situ and invasive ductal car...
Next Document:  Symptom interval in young people with bone cancer.